Cipla Past Earnings Performance

Past criteria checks 5/6

Cipla has been growing earnings at an average annual rate of 19.7%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.2% per year. Cipla's return on equity is 15.7%, and it has net margins of 17%.

Key information

19.7%

Earnings growth rate

19.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate9.2%
Return on equity15.7%
Net Margin17.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cipla makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:500087 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24262,64244,75157,3450
30 Jun 24258,92243,03556,1780
31 Mar 24255,36741,21654,9010
31 Dec 23251,16337,08253,7570
30 Sep 23243,40734,53252,5630
30 Jun 23235,10831,11251,2600
31 Mar 23225,59328,01950,1510
31 Dec 22222,18726,38348,9470
30 Sep 22218,87425,66048,1840
30 Jun 22216,10524,88435,9840
31 Mar 22217,07825,16846,6690
31 Dec 21210,71825,68143,2850
30 Sep 21207,61625,87643,0040
30 Jun 21202,80125,41742,4350
31 Mar 21191,20524,04941,2810
31 Dec 20188,77922,37440,4320
30 Sep 20180,80218,40339,4440
30 Jun 20174,37716,46238,8510
31 Mar 20170,80515,46538,6940
31 Dec 19171,20616,67838,6080
30 Sep 19167,57216,48938,3310
30 Jun 19163,73315,54637,8370
31 Mar 19163,23215,27737,4150
31 Dec 18155,22413,39135,6830
30 Sep 18154,28714,07435,0780
30 Jun 18154,99214,53034,5640
31 Mar 18151,05314,10534,1510
31 Dec 17147,61811,70132,9730
30 Sep 17144,95111,44432,7300
30 Jun 17141,63710,76232,8750
31 Mar 17143,34010,06433,0110
31 Dec 16142,50911,21331,5540
30 Sep 16137,54710,07131,0120
30 Jun 16134,33512,21930,0890
31 Mar 16135,48013,60029,2580
31 Dec 15135,04416,84739,0281,120
30 Sep 15131,63316,69438,2201,120
30 Jun 15124,78215,36837,0961,120
31 Mar 15113,45411,80823,5490
31 Dec 14106,19511,81832,1561,058
30 Sep 14105,62711,38331,3331,058
30 Jun 14104,16411,97630,2241,058
31 Mar 14101,73413,88429,5461,058
31 Dec 1394,33014,04225,122432

Quality Earnings: 500087 has high quality earnings.

Growing Profit Margin: 500087's current net profit margins (17%) are higher than last year (14.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 500087's earnings have grown by 19.7% per year over the past 5 years.

Accelerating Growth: 500087's earnings growth over the past year (29.6%) exceeds its 5-year average (19.7% per year).

Earnings vs Industry: 500087 earnings growth over the past year (29.6%) exceeded the Pharmaceuticals industry 20.4%.


Return on Equity

High ROE: 500087's Return on Equity (15.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:02
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cipla Limited is covered by 74 analysts. 37 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited